SELLAS Life Sciences Group, Inc. (FRA:RXK3)
Germany
· Delayed Price · Currency is EUR 1.294
+0.090 (7.48%)
At close: Dec 4, 2025
FRA:RXK3 Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | - | - | - | 1 | 7.6 | 1.9 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | -86.84% | 300.00% | - | Upgrade
|
| Cost of Revenue | - | - | - | 0.1 | 0.2 | - | Upgrade
|
| Gross Profit | - | - | - | 0.9 | 7.4 | 1.9 | Upgrade
|
| Selling, General & Admin | 12.31 | 12.42 | 13.86 | 12.58 | 11.32 | 9.6 | Upgrade
|
| Research & Development | 15.73 | 19.1 | 24.01 | 20.27 | 15.67 | 9.28 | Upgrade
|
| Operating Expenses | 28.04 | 31.51 | 37.87 | 32.85 | 26.99 | 18.88 | Upgrade
|
| Operating Income | -28.04 | -31.51 | -37.87 | -31.95 | -19.59 | -16.98 | Upgrade
|
| Interest & Investment Income | 1 | 0.63 | 0.53 | 0.32 | 0.01 | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 0 | 0.04 | 0.02 | -0.1 | Upgrade
|
| EBT Excluding Unusual Items | -27.04 | -30.88 | -37.34 | -31.6 | -19.57 | -17.05 | Upgrade
|
| Other Unusual Items | 1.1 | - | - | 0.3 | 4.34 | 0.28 | Upgrade
|
| Pretax Income | -25.94 | -30.88 | -37.34 | -41.3 | -20.94 | -16.77 | Upgrade
|
| Income Tax Expense | - | - | - | - | -0.24 | -0.02 | Upgrade
|
| Net Income | -25.94 | -30.88 | -37.34 | -41.3 | -20.7 | -16.76 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.08 | Upgrade
|
| Net Income to Common | -25.94 | -30.88 | -37.34 | -41.3 | -20.7 | -16.84 | Upgrade
|
| Shares Outstanding (Basic) | 92 | 61 | 28 | 19 | 15 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 92 | 61 | 28 | 19 | 15 | 8 | Upgrade
|
| Shares Change (YoY) | 82.98% | 120.33% | 43.21% | 25.29% | 94.07% | 211.76% | Upgrade
|
| EPS (Basic) | -0.28 | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 | Upgrade
|
| EPS (Diluted) | -0.28 | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 | Upgrade
|
| Free Cash Flow | -30.62 | -35.4 | -31.41 | -23.81 | -26.02 | -10.42 | Upgrade
|
| Free Cash Flow Per Share | -0.33 | -0.58 | -1.13 | -1.23 | -1.68 | -1.31 | Upgrade
|
| Gross Margin | - | - | - | 90.00% | 97.37% | 100.00% | Upgrade
|
| Operating Margin | - | - | - | -3195.00% | -257.82% | -893.79% | Upgrade
|
| Profit Margin | - | - | - | -4130.10% | -272.36% | -886.05% | Upgrade
|
| Free Cash Flow Margin | - | - | - | -2380.90% | -342.38% | -548.26% | Upgrade
|
| EBIT | -28.04 | -31.51 | -37.87 | -31.95 | -19.59 | -16.98 | Upgrade
|
| EBIT Margin | - | - | - | - | -257.82% | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.